EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical and Pathological Features of Patients with Multiple Endocrine Neoplasia Type 1: A Long-Term Comparative Analysis Between Exon 2 and Other Mutations in the MEN1 Gene

Elio Benevento, Alessia Liccardi, Roberto Minotta, Gianfranco Di Iasi, Massimo Di Nola, Michele Coletta, Annamaria Colao, Roberta Modica

Metabolites · 2026-11-06 · 16 (11) · 859

DOI: 10.3390/metabo16110859 ↗
AbstractBibliografische Angaben

Abstract

Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited syndrome characterized by primary hyperparathyroidism (PHPT), duodenopancreatic neuroendocrine tumors (DP-NET), pituitary NET (Pit-NET) and other endocrine neoplasms. Reliable genotype–phenotype correlations remain limited, and the clinical relevance of MEN1 exon 2 variants is still uncertain. Methods and aim: This monocentric retrospective cohort included genetically confirmed MEN1 patients followed at the University of Naples Federico II from January 1992 to April 2025. Eligible patients carried a pathogenic MEN-1 variant involving a single exon and had at least 36 months of follow-up. Clinical, biochemical, radiological, histopathological, genetic, and treatment data were reviewed to compare patients carrying exon 2 variants (Ex2) with those carrying variants in other exons (OtherEx) in order to evaluate mean age at diagnosis (TD) and aggressiveness of MEN-1 manifestations in these two groups. Results: Sixty patients were included: 21 Ex2 and 39 OtherEx. Follow-up was comparable between groups (133 +/− 47.7 vs. 128 +/− 50.0 months). PHPT, Pit-NET, and DP-NET had similar prevalence. DP-NET metastases were more frequent in Ex2 than OtherEx patients (4/21, 19.0% vs. 1/39, 2.6%; OR 8.94, 95% CI 0.93–86.09; p = 0.0465). When the analysis was restricted to patients who developed DP-NET, metastatic disease occurred in 4/16 Ex2 patients (25.0%) and 1/30 OtherEx patients (3.3%; OR 9.67, 95% CI 0.98–95.68; p = 0.0430). Mean DP-NET progression-free survival was numerically shorter in Ex2 patients, without statistical significance (99.6 vs. 121.6 months; p = 0.27), and DP-NET-related deaths occurred only in the Ex2 group. Additional exploratory signals included male-specific adrenal adenomas among Ex2 patients and exon 7-related bone impairment. Conclusions: This long-term MEN1 cohort suggests that exon 2 variants may identify patients with similar DP-NET prevalence but greater metastatic propensity. Because of the number of metastatic events, these findings require validation in larger multicenter cohorts.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →